UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025

+ Include: 27 Videos (.mp4) + 27 Audios (.mp3) + 27 Subtitles (.vtt) + 26 PDFs, size: 9.29 GB

+ Target Audience: practicing oncologists, hematologists

+ Information:

1. Overview

The UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025 provides an in-depth review of the latest clinical advancements in lymphoma diagnosis and management. The course explores novel targeted therapies, cellular treatments like CAR T-cells and bispecifics, genomic testing, and multidisciplinary strategies for managing complex and relapsed lymphoma cases.

Course Date: 04/04/2025

2. Learning Objectives

• At the conclusion of this educational activity, participants will be able to:
  • Assess clinical trial results of approved and investigational treatment strategies being studied in patients with indolent and aggressive subtypes of B-cell and T-cell non-Hodgkin lymphoma
  • Compare and contrast the selection and sequencing of therapeutic approaches for the care of patients with newly diagnosed and relapsed/refractory Hodgkin lymphoma
  • Evaluate the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL/SLL
  • Review approaches to the care of patients with rarer hematologic malignancies, including CNS lymphoma and Waldenstrom macroglobulinemia
  • Identify and nurture strategies to enhance communication and collaboration with the entire multidisciplinary healthcare team during the continuum of care of patients with lymphoma

3. Target Audience

Best for hematologists and oncologists who want updates on cellular therapies, genomic testing, and clinical management of complex lymphomas.

The target audience for this symposium is practicing oncologists, hematologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.

4. Topics

• 01 Nivo-AVD for Advanced Stage Hodgkin Lymphoma

• 02 Bv-AVD for Advanced Stage Hodgkin Lymphoma

• 03 Contributions of the European Regimens to the Management of cHL

• 04 The Impact of 1L Therapy Selection on Subsequent HL Treatment Approaches

• 05 Prioritizing Clinical Research in Oncology Clinical Practice

• 06 Comparison of CAR T-Cell Therapies in RR Follicular Lymphoma

• 07 Comparison of Bispecific Therapies in RR Follicular Lymphoma

• 08 Non-T-Cell Engaging Treatment Options in RR Follicular Lymphoma

• 09 How I Approach Treatment-Naive CLL SLL

• 10 Challenges in Treating Patients with TP53-Mutated MCL

• 11 Role of Transplant and Cellular Therapy in RR MCL

• 12 Globalizing Lymphoma Research – Challenges and Opportunities

• 13 Current Role of BTK Inhibitors in Frontline MCL

• 14 Overview of Treatment Options and Key Trials for CNS Lymphoma

• 15 A Ticking Time B-Cell Lymphoma – A Case on High-Risk DLBCL for CNS Relapse

• 16 Challenging Case Discussion – Newly Diagnosed Low-Grade FL Transformed Into Double-hit DLBCL With Secondary CNS Lymph…

• 17 Frontline Treatment Options in Newly Diagnosed DLBCL

• 18 RR DLBCL – The Role of CAR T-Cells vs. Bispecifics in First Relapse

• 19 FrailOlder Patients With DLBCL – A Persistent Challenge

• 20 Baseline Genomic Testing in Lymphoma – Are We There Yet

• 21 Next Generation Hematopathology and the Standard of Care in Lymphoma

• 22 Mediastinal Gray Zone Lymphoma Case-Based Panel Discussion – Diagnostic Criteria & Management Approach

• 23 Novel Therapies for Lymphoma – Focus on CELMoDs and BTK Degraders

• 24 Novel T-Cell Engaging Therapy Approaches – How Close are They to Prime Time

• 25 Improving HRQoL for Patients With Lymphoma

• 26 Nursing Perspective on Managing Neurotoxicity – What Tools Do We Have

• 27 Incorporating Patient-Reported Outcomes in Clinical Trials